Business Context and Reporting Period
Company: CVS Corporation (CVS Health Corp)
Filing Type: Form 10-K Annual Report
Reporting Period: Fiscal year ended December 30, 2006 (52 weeks)
Business Overview: CVS is a leader in the U.S. retail drugstore industry, operating 6,202 retail and specialty pharmacy stores across 43 states and the District of Columbia. The company operates two primary business segments: Retail Pharmacy and Pharmacy Benefit Management (PBM). In 2006, CVS filled approximately 513 million retail adjusted prescriptions, representing 16.0% of the U.S. retail pharmacy market.
Key Financial Metrics
| Metric | 2006 (in millions) | 2005 (in millions) |
|---|---|---|
| Net Revenues | $43,813.8 | $37,006.2 |
| Gross Profit | $11,939.0 | $9,901.2 |
| Operating Profit | $2,441.6 | $2,019.5 |
| Net Earnings | $1,368.9 | $1,224.7 |
| Diluted EPS | $1.60 | $1.45 |
| Total Assets | $20,569.8 | $15,283.4 |
| Long-term Debt | $2,870.4 | $1,594.1 |
| Shareholders' Equity | $9,917.6 | $8,331.2 |
Revenue Composition (2006): Prescription drugs accounted for 70% of net revenues, while over-the-counter and personal care products represented 12%. Managed care and third-party plans accounted for 95% of pharmacy revenues.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 18.4% to $43.8 billion, driven primarily by the acquisition of the Standalone Drug Business from Albertson's, Inc. for $4.0 billion in June 2006, which added approximately 700 standalone drugstores.
- Store Count: Total store count increased from 5,471 in 2005 to 6,202 in 2006. Net selling space increased 23.3% to 55.5 million square feet.
- Profitability: Operating profit rose 20.9% to $2.44 billion, and net earnings increased 11.8% to $1.37 billion.
- Debt Levels: Long-term debt increased significantly to $2.87 billion from $1.59 billion, reflecting financing for the Albertson's acquisition and other capital needs.
- Dividends: Cash dividends per share increased to $0.1550 in 2006 from $0.1450 in 2005. In January 2007, the Board authorized a 26% increase in the quarterly dividend.
Guidance, Outlook, and Risks
Proposed Merger with Caremark
On November 1, 2006, CVS entered into a definitive merger agreement with Caremark Rx, Inc. The transaction is structured as a merger of equals, with Caremark shareholders receiving 1.670 shares of CVS stock per share. The deal includes a special one-time cash dividend of $6 per share to Caremark shareholders and an accelerated share repurchase of 150 million shares by the combined company. Closing is expected in the first quarter of 2007, subject to shareholder and regulatory approvals.
Management Commentary and Outlook
- Store Development: CVS expects to open approximately 275 new or relocated stores in 2007.
- Medicare Part D: The company notes that the transition of dual-eligible participants from Medicaid to Medicare Part D has resulted in lower margin rates, though no further significant decrease is expected in 2007.
- Integration: Management anticipates the merger will be accretive to earnings per share in the first full calendar year post-merger, though integration costs and accounting charges may impact near-term results.
Risks and Contingencies
- Merger Risks: Failure to complete the merger could result in a $675 million termination fee and diversion of management attention. Regulatory approval and shareholder votes remain pending.
- Legal Proceedings:
- SEC Inquiry: The SEC is investigating accounting entries related to a 2000 transaction involving plush toy inventory and barter credits. The Audit Committee concluded the accounting was incorrect, but no financial statement adjustments were required.
- State Investigations: Ongoing investigations by the Rhode Island Attorney General and federal authorities regarding business relationships with a former state senator. Two CVS employees were indicted in January 2007.
- Generic Drug Dispensing: DOJ and state attorneys general are investigating practices regarding the dispensing of different dosage forms of generic drugs.
- Merger Litigation: Multiple shareholder lawsuits have been filed challenging the Caremark merger, alleging breaches of fiduciary duty and inadequate disclosure. Shareholder votes have been delayed by the Delaware Court of Chancery.
- Regulatory Environment: Changes in Medicaid reimbursement formulas (Deficit Reduction Act of 2005) and potential shifts in Medicare Part D risk corridors in 2008 pose financial risks.
Key Facts for Investor Verification
- Merger Status: Verify the final status of the Caremark merger, including shareholder vote outcomes and regulatory approvals, as the filing indicates significant delays and litigation.
- Legal Exposure: Monitor the outcome of the SEC inquiry regarding the 2000 transaction and the indictments of CVS employees related to the Rhode Island political investigation.
- Debt Servicing: Assess the impact of the increased long-term debt ($2.87 billion) on liquidity and interest coverage ratios, particularly in light of the pending merger financing.
- Medicare Part D Impact: Evaluate the long-term margin compression effects of the Medicare Part D program on the pharmacy segment.
- Integration Costs: Review future filings for actual integration costs and synergies realized from the Caremark merger versus management's preliminary estimates.